In this study, we assembled a panel of RAS- and NF1-altered neuroblastoma cell lines with variable IGF1R expression to evaluate the efficacy of the combination of a MEK inhibitor (trametinib) and an IGF1R inhibitor (ganitumab) in neuroblastoma. This evidence concerns the gene IGF1R and neuroblastoma.